Lansoprazole-d4 |
Catalog No.GC47537
One-Click Copy Product Info
|
Le lansoprazole D4 (AG-1749 D4) est un lansoprazole marqué au deutérium.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 934294-22-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Lansoprazole-d4 is intended for use as an internal standard for the quantification of lansoprazole by GC- or LC-MS. Lansoprazole is a proton pump inhibitor that inhibits the H+/K+-ATPase.1 It inhibits K+ and H+ accumulation in gastric microsomes in a concentration-dependent manner (IC50s = 6.3 and 7 µM, respectively) and inhibits H+/K+-ATPase activity by approximately 60% when used at a concentration of 10 µM. Lansoprazole inhibits the H+/K+-ATPase in parietal cells, thus inhibiting gastric acid secretion and increasing intragastric pH.2 It is a substituted benzimidazole that binds covalently to proton pumps, providing complete and prolonged inhibition of acid secretion.3,4 Formulations containing lansoprazole have been used as a proton pump inhibitor and in combination with antibiotics in the treatment of H. pylori infections and duodenal ulcer disease.
1.Nagaya, H., Satoh, H., Kubo, K., et al.Possible mechanism for the inhibition of gastric (H+ + K+)-adenosine triphosphatase by the proton pump inhibitor AG-1749J. Pharmacol. Exp. Ther.248(2)799-805(1989) 2.Schubert, M.L.Pharmacotherapy for acid/peptic disordersYale J. Biol. Med.69(2)197-201(1996) 3.Richardson, P., Hawkey, C.J., and Stack, W.A.Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disordersDrugs56(3)307-335(1998) 4.Klotz, U.Pharmacokinetic considerations in the eradication of Helicobacter pyloriClin. Pharmacokinet.38(3)243-270(2000)
| Cas No. | 934294-22-1 | SDF | |
| Canonical SMILES | CC1=C(CS(C2=NC(C([2H])=C([2H])C([2H])=C3[2H])=C3N2)=O)N=CC=C1OCC(F)(F)F | ||
| Formula | C16H10D4F3N3O2S | M.Wt | 373.4 |
| Solubility | DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 5 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6781 mL | 13.3905 mL | 26.7809 mL |
| 5 mM | 535.6 μL | 2.6781 mL | 5.3562 mL |
| 10 mM | 267.8 μL | 1.339 mL | 2.6781 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 8 reference(s) in Google Scholar.)